Michael Keiley, MD
Allergy & Immunology · Boise, IDNPI 1679569149
Payments from drug & device makers
Across 362 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$906
- Regeneron Healthcare Solutions, Inc.$779
- CSL Behring$679
- Grifols USA, LLC$655
- Takeda Pharmaceuticals U.S.A., Inc.$409
- plus $2K from 30 others
What the payments were for
- Consulting fees$130%
- Food & beverage$6,75798%
- Education$1352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 71 | $1,223 |
| GSK | 67 | $906 |
| Regeneron Healthcare Solutions, Inc. | 37 | $779 |
| CSL Behring | 30 | $679 |
| Grifols USA, LLC | 32 | $655 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $409 |
| Genentech USA, Inc. | 14 | $314 |
| Blueprint Medicines Corporation | 12 | $284 |
| Amgen | 11 | $219 |
| Sanofi | 10 | $207 |
| Kaleo, Inc. | 4 | $162 |
| Novartis | 8 | $155 |
| Octapharma USA, Inc. | 2 | $119 |
| Pharming Healthcare, Inc. | 4 | $97 |
| Aimmune Therapeutics, Inc. | 5 | $94 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $66 |
| Pfizer | 5 | $64 |
| Incyte Corporation | 4 | $61 |
| Verona Pharma, Inc. | 2 | $55 |
| Biocryst US Sales Co., LLC | 2 | $45 |
| Boehringer Ingelheim | 2 | $39 |
| Galderma Laboratories, L.p. | 2 | $38 |
| Tersera Therapeutics LLC | 1 | $24 |
| Ionis Pharmaceuticals, Inc. | 1 | $22 |
| Organon | 2 | $21 |
| Sanofi US Services Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| AbbVie | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Circassia Inc. | 1 | $13 |
| ADMA Biomanufacturing LLC | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
| Bio Products Laboratory USA, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy & immunology providers in Idahoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CinryzeC1 Esterase Inhibitor | 13 | $1,714,728 |
| BerinertC1 Esterase Inhibitor | 13 | $596,813 |
| Dupixent PenDupilumab | 58 | $223,006 |
| XolairOmalizumab | 29 | $118,233 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 148 | $107,283 |
| Dupixent SyringeDupilumab | 26 | $98,142 |
| Advair HfaFluticasone Propion/Salmeterol | 55 | $23,410 |
| Spiriva RespimatTiotropium Bromide | 31 | $22,403 |
| Qvar RedihalerBeclomethasone Dipropionate | 47 | $11,379 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 48 | $9,116 |
| DuleraMometasone/Formoterol | 22 | $8,981 |
| Ipratropium Bromide | 296 | $8,570 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $7,858 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,298 |
| Fluticasone Propionate HfaFluticasone Propionate | 29 | $5,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Cinryze | $409 | $1,714,72813 claims |
| CSL BehringBerinert | $679 | $596,81313 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $906 | $118,367182 claims |
| Boehringer IngelheimSpiriva Respimat | $39 | $22,40331 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $19 | $11,37947 claims |
| MerckDulera | $15 | $8,98122 claims |
| AstraZenecaSymbicort | $1,223 | $7,85831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Idahoon file to place this against a meaningful peer group, so we don't.
Other allergy & immunology in Boise
- John JeppsonBoise$65K
- George PalmerBoise$9K
- Sean StoutBoise$5K
- Jeremy WaldramBoise$2K
- Wendell PettyIdaho Falls$12K
- Shayne StokesTwin Falls$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.